Ngl Fine-chem Ltd. · NSE:NGLFINE
Ngl Fine-chem — Q2 & H1 FY25 Earnings Presentation
18 slides from Ngl Fine-chem's earnings presentation, Nov 11, 2024
Slide 1: Exchange filing cover letter
Regd. Office 301, E – Square, Subhash Road, Vile Parle East, Mumbai 400057 Maharashtra, India. Tel.: (+91 22) 40842222, Fax: (+91 22) 2610 8030, Email: info@nglfinechem.com CIN L24110MH1981PLC025884,Website www.nglfinechem.com November 11, 2024 To, Listing Department, Listing Department, The BSE Lim
Slide 2: Investor Presentation Q2 & H1 FY25
NGL Fine-Chem Limited IN V ES TO R P RE SE N TAT ION Q2 & H1 FY25
Slide 3: Disclaimer
Disclaimer This investor presentation has been prepared by NGL Fine-Chem Limited and does not constitute a prospectus or placement memorandum or an offer to acquire any securities. This presentation or any other documentation or information (or any part thereof) delivered or supplied should not be d
Slide 4: Inside
Inside Pg. No. Pg. No. This Presentation 04 08 Q2 & H1 Over view, FY25 Key Strengths Highlights and Strategy Pg. No. 13 Historical Financial Performance
Slide 5: Q2 & H1FY25 Highlights
01 Q2 & H1FY25 Highlights 05 M A N AG E M E N T C O M M E N TA R Y 06 Q UA R T E R LY O PE R AT IO N A L M E T R IC S 07 S U M M A R Y O F P RO FI T A N D LO S S S TAT E M E N T 08 S UM M A R Y O F B A L A N C E S H E E T 09 S UM M A R Y O F C A S H F LO W S TAT E M E N T
Slide 6: Management Commentary
MANAGEMENT COMMENTARY Dear Shareholders, S u it ab il ity (CEP) f or a n e w p r od u ct. W e n o w I a m p le a se d to p r ov id e a n u p da te o n N G L F in e h a ve f ou r Dr u g M a ste r F il es (DM F ) a pp r ov e d Ch e m L imi te d 's p e rf o r ma n ce f or Q 2 F Y2 5. Th e f or th e Eu
Slide 7: Operational Metrics
Operational Metrics SEGMENTAL REVENUE MIX PRODUCT CONCENTRATION PARTICULARS Q2FY24 Q1FY25 Q2FY25 PARTICULARS Q2FY24 Q1FY25 Q2FY25 ANIMAL API 83% 90% 94% TOP 3 PRODUCTS 29% 32% 38% HUMAN API 6% 5% 3% TOP 5 PRODUCTS 41% 47% 51% INTERMEDIATES 5% 3% 2% TOP 10 PRODUCTS 65% 71% 72% FORMULATIONS 6% 2% 2% G
Slide 8: Summary of Profit and Loss Statement
Summary of Profit and Loss Statement ₹ I N CR O RES PA RT I CULA RS Q2FY24 Q1FY25 Q2FY25 Q-o-Q Y-o-Y H1FY24 H1FY25 Y-o-Y REVENUE FROM OPERATIONS 80.18 90.75 93.48 3.01% 16.60% 151.22 184.24 21.83% OTHER INCOME 3.22 5.88 5.12 -13.07% 58.91% 6.54 11.00 68.18% TOTAL INCOME 83.40 96.64 98.60 2.03% 18.23
Slide 9: Summary of Balance Sheet
Summary of Balance Sheet ₹ I N CR O RES PA RT I CULA RS FY24 H1FY25 SHAREHOLDERS FUND 262.63 280.29 NON CURRENT LIABILITIES 6.32 27.11 LONG TERM BORROWINGS 0.74 19.60 CURRENT LIABILITIES 86.59 88.45 SHORT TERM BORROWINGS 31.70 29.60 TOTAL EQUITY AND LIABILITIES 355.54 395.85 NON CURRENT ASSETS 142.8
Slide 10: Summary of Cash Flow Statement
Summary of Cash Flow Statement ₹ I N CR O RES PA RT I CULA RS FY24 H1FY25 CASH FLOW FROM OPERATING ACTIVITIES 14.73 7.74 CASH FLOW FROM INVESTING ACTIVITIES (21.09) (1.05) CASH FLOW FROM FINANCING ACTIVITIES (1.08) (1.08) NET CASH FLOW (7.43) 5.60 CASH AT THE BEGINNING OF YEAR 7.83 0.40 CASH AT THE
Slide 11: Overview, Strengths and Strategy
02 Overview, Strengths and Strategy 11 L E A D I N G A N IM A L H E A LT H C O M PA N Y 12 L E A D E R S H I P IN V E T E R IN A RY A P I S E G M E N T 13 S TAT E - O F - T H E - A R T M A N U FA C T U R I N G C A PA BI L I T I E S 14 S T R AT E G Y F O R N E X T L E G O F G R O W T H
Slide 12: Leading Animal Health Company
Leading Animal Health Company COMPREHENSIVE MARKET MANUFACTURING LARGE GLOBAL LONG STANDING PRODUCT LEADERSHIP EXCELLENCE PRESENCE CUSTOMER PORTFOLIO IN VETERINARY API RELATIONSHIPS • 32 APIs (30 Veterinary • Leadership in top • 3 state of the art • 50+ countries across • ~400 customers APIs, 2 Huma
Slide 13: Leadership in Veterinary API Segment
Leadership in Veterinary API Segment REVENUE FROM VETERINARY CUSTOMER & PRODUCT Strong controls of processes with 95% in-house manufacturing and API SEGMENT ( ₹ IN C RO RE S) 22% CAGR CONCENTRATION (OF SALES FY24) backward integrated facilities leading to cost competitiveness FY24 300 CUSTOMER PRODU
Slide 14: State-of-the-art Manufacturing Capabilities
State-of-the-art Manufacturing Capabilities HIGHLIGHTS 3 manufacturing facilities located at Tarapur & Navi 10,000 m 2 102 m 3 194 m 3 AREA OF GLASS-LINED STAINLESS STEEL Mumbai, Maharashtra, MANUFACTURING REACTORS REACTORS designed to meet the FACILITIES requirements of regulatory agencies and are
Slide 15: Strategy for next leg of growth
Strategy for next leg of growth BROWNFIELD EXPANSIO N • Completed expansion in ONGOING INITIATIVES subsidiary Macrotech TO INCREASE • Additional capacities of a CAPACITIES TO MEET intermediates GROWING DEMAND • Commercial production started GREENFIELD EXPANSIO N AT TARAP UR • 50% capacity expansion
Slide 16: Historical Financial Performance
03 Historical Financial Performance 16 R O B US T FI N A N C I A L PE R F O R M A N C E
Slide 17: Robust Financial Performance
Robust Financial Performance REVENUE EBITDA PAT (₹ I N C RORES) (₹ I N C RORES) (₹ I N C RORES) FY24 339 FY24 53 FY24 41 FY23 278 FY23 34 FY23 21 FY22 318 FY22 68 FY22 50 FY21 258 FY21 80 FY21 57 FY20 152 FY20 19 FY20 8 0 50 10 0 15 0 20 0 25 0 30 0 35 0 40 0 0 10 20 30 40 50 60 70 80 90 0 10 20 30
Slide 18: Thank You
FOR ANY FURTHER INFORMATION, PLEASE CONTACT Thank You Pallavi Pednekar Abhishek Mehra NG L F I NE - C H E M T I L A D VI S O R S P R I V A T E L I MI TE D L I MI TED cs@nglfinechem.com abhishek@theinvestmentlab.in +91 22 40842222 +91 95588 14500 Corporate Office 3 01 , E- s q u a r e, S u b h a sh R